X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Using traditional HTAs to determine coverage threatens patient access to medicine

By Katie Koziara  |    December 14, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Traditional HTAs keep diverse patients out of the conversation

By Katie Koziara  |    December 7, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

How HTA-based price controls could worsen health outcomes and health disparities

By Katie Koziara  |    November 22, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Traditional HTA methods treat everyone like the “average” patient

By Katie Koziara  |    November 7, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important...   Read More

Value assessment should include all aspects of value that matter to patients

By Emilie Signora  |    August 10, 2022
We need to move toward a more value-driven health care system that centers around patients’ needs. Sound evidence can help guide us toward that, and we’re committed to developing tools to help...   Read More

You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities

By Jackie McRae  |    June 16, 2022
A new report from Partnership for Health Analytic Research or PHAR describes how value assessments that use traditional cost-effectiveness analyses can overlook important health disparities and risk...   Read More

PhRMA presents research at ISPOR 2022

By Jackie McRae  |    May 26, 2022
Last week at the ISPOR annual international meeting, PhRMA partnered with multiple organizations committed to advancing value assessment research and methods. We worked with a range of academics,...   Read More

Creating a new patient risk paradigm in American health care

By Guest Contributor  |    May 18, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the authors...   Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

By Holly Campbell  |    September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates